Aptevo Therapeutics Inc. - Common stock, par value $0.001 per share (APVO)
CUSIP: 03835L405
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Shares outstanding
- 3,581,500
- Total 13F shares
- 19,629
- Share change
- -28,862
- Total reported value
- $22,769
- Price per share
- $1.16
- Number of holders
- 8
- Value change
- -$168,977
- Number of buys
- 5
- Number of sells
- 7
Quarterly Holders Quick Answers
What is CUSIP 03835L405?
CUSIP 03835L405 identifies APVO - Aptevo Therapeutics Inc. - Common stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03835L405:
Top shareholders of APVO - Aptevo Therapeutics Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Virtu Financial LLC |
13F
|
Company |
0.6%
|
21,627
|
$93,000 | — | 31 Dec 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.34%
|
12,324
|
$53,000 | — | 31 Dec 2024 | |
| Hudson Bay Capital Management LP |
13D/G
|
— |
5%
|
76,598
|
$52,853 | $0 | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.13%
|
4,529
|
$19,520 | — | 31 Dec 2024 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.11%
|
4,050
|
$17,456 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.11%
|
3,927
|
$16,925 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.03%
|
1,086
|
$4,680 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
783
|
$3,375 | — | 31 Dec 2024 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
131
|
$565 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
24
|
$103 | — | 31 Dec 2024 | |
| Center for Financial Planning, Inc. |
13F
|
Company |
0%
|
5
|
$22 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
4
|
$17 | — | 31 Dec 2024 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$4 | — | 31 Dec 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1
|
$4 | — | 31 Dec 2024 | |
| Fuad El-Hibri |
3/4/5
|
Director |
—
class O/S missing
|
87,697
|
— | — | 03 Dec 2021 |
Institutional Holders of Aptevo Therapeutics Inc. - Common stock, par value $0.001 per share (APVO) as of Q1 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.